4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-19-013821
Director sold 68,000 shares at an average $19.20 ($1,305,400)
- Director acquired 65,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GIVEN DOUGLAS B Director | 2019-02-22 | Sale | −3,000 | $18.05 | $54,150 | 175,130 | D: show line 1 in the form |
| GIVEN DOUGLAS B Director | 2019-02-26 | Option exercise | +30,000 | $5.19 | $155,700 | 205,130 | D: show line 2 in the form |
| GIVEN DOUGLAS B Director | 2019-02-26 | Option exercise | +18,000 | $2.19 | $39,420 | 223,130 | D: show line 3 in the form |
| GIVEN DOUGLAS B Director | 2019-02-26 | Option exercise | +10,000 | $2.62 | $26,200 | 233,130 | D: show line 4 in the form |
| GIVEN DOUGLAS B Director | 2019-02-26 | Option exercise | +7,000 | $4.75 | $33,250 | 240,130 | D: show line 5 in the form |
| GIVEN DOUGLAS B Director | 2019-02-26 | Sale | −65,000 | $19.25 | $1,251,250 | 175,130 | D: show line 6 in the form |
| Open-market sales · 68,000 sh · avg $19.20 · $1,305,400 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| GIVEN DOUGLAS B Director | 2019-02-26 | Option exercise · Stock Option (right to buy) | −30,000 | 35,000 | D: show line 7 in the form | |||||
| GIVEN DOUGLAS B Director | 2019-02-26 | Option exercise · Stock Option (right to buy) | −18,000 | 17,000 | D: show line 8 in the form | |||||
| GIVEN DOUGLAS B Director | 2019-02-26 | Option exercise · Stock Option (right to buy) | −10,000 | 7,000 | D: show line 9 in the form | |||||
| GIVEN DOUGLAS B Director | 2019-02-26 | Option exercise · Stock Option (right to buy) | −7,000 | 0 | D: show line 10 in the form |
Loading xslF345X03/doc4.xml…